Aggregate data meta-analysis with time-to-event outcomes
- PMID: 12407676
- DOI: 10.1002/sim.1303
Aggregate data meta-analysis with time-to-event outcomes
Abstract
In a meta-analysis of randomized controlled trials with time-to-event outcomes, an aggregate data approach may be required for some or all included studies. Variation in the reporting of survival analyses in journals suggests that no single method for extracting the log(hazard ratio) estimate will suffice. Methods are described which improve upon a previously proposed method for estimating the log(HR) from survival curves. These methods extend to life-tables. In the situation where the treatment effect varies over time and the trials in the meta-analysis have different lengths of follow-up, heterogeneity may be evident. In order to assess whether the hazard ratio changes with time, several tests are proposed and compared. A cohort study comparing life expectancy of males and females with cerebral palsy and a systematic review of five trials comparing two anti-epileptic drugs, carbamazepine and sodium valproate, are used for illustration.
Copyright 2002 John Wiley & Sons, Ltd.
Similar articles
-
Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes.Stat Med. 2005 May 15;24(9):1307-19. doi: 10.1002/sim.2050. Stat Med. 2005. PMID: 15685717
-
An overview of methods and empirical comparison of aggregate data and individual patient data results for investigating heterogeneity in meta-analysis of time-to-event outcomes.J Eval Clin Pract. 2005 Oct;11(5):468-78. doi: 10.1111/j.1365-2753.2005.00559.x. J Eval Clin Pract. 2005. PMID: 16164588
-
Evidence-based medicine, systematic reviews, and guidelines in interventional pain management: part 6. Systematic reviews and meta-analyses of observational studies.Pain Physician. 2009 Sep-Oct;12(5):819-50. Pain Physician. 2009. PMID: 19787009
-
The treatment of the first seizure: the benefits.Epilepsia. 2008;49 Suppl 1:26-8. doi: 10.1111/j.1528-1167.2008.01446.x. Epilepsia. 2008. PMID: 18184151 Review.
-
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).Amyotroph Lateral Scler Other Motor Neuron Disord. 2003 Sep;4(3):191-206. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003. PMID: 13129806 Review.
Cited by
-
Prognostic Role of Secretory Clusterin in Multiple Human Malignant Neoplasms: A Meta-Analysis of 26 Immunohistochemistry Studies.PLoS One. 2016 Aug 17;11(8):e0161150. doi: 10.1371/journal.pone.0161150. eCollection 2016. PLoS One. 2016. Retraction in: PLoS One. 2023 May 4;18(5):e0285567. doi: 10.1371/journal.pone.0285567. PMID: 27532124 Free PMC article. Retracted.
-
Pre-treatment Glasgow prognostic score and modified Glasgow prognostic score may be potential prognostic biomarkers in urological cancers: a systematic review and meta-analysis.Ann Transl Med. 2019 Oct;7(20):531. doi: 10.21037/atm.2019.09.160. Ann Transl Med. 2019. PMID: 31807513 Free PMC article.
-
EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis.Chin J Cancer Res. 2014 Feb;26(1):59-71. doi: 10.3978/j.issn.1000-9604.2014.01.10. Chin J Cancer Res. 2014. PMID: 24653627 Free PMC article.
-
Relationship between NAMPT/PBEF/visfatin and prognosis of patients with malignant tumors: a systematic review and meta-analysis.Ann Transl Med. 2019 Dec;7(23):785. doi: 10.21037/atm.2019.11.32. Ann Transl Med. 2019. PMID: 32042801 Free PMC article.
-
Expression of caveolin-1 in breast cancer stroma as a potential prognostic biomarker of survival and progression: a meta-analysis.Wien Klin Wochenschr. 2017 Aug;129(15-16):558-563. doi: 10.1007/s00508-017-1173-3. Epub 2017 Mar 31. Wien Klin Wochenschr. 2017. PMID: 28364168